Resources

PIR International was delighted to partner with Slingshot Therapeutics on the appointment of Bobby Soni as Chief Business Officer.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Vicore Pharma Holding AB (STO: VICO) and is pleased to announce the placement of Katrine Husum as R&D Senior Project Director.

This blog explores the transformative BIA MAC Leadership Programme (LeaP) — a unique initiative empowering emerging bioprocessing professionals to accelerate their careers and strengthen leadership across the UK life sciences sector. With 76% of participants reporting career progression, LeaP is shaping the next generation of biotech leaders.

Research shows that while 85% of biopharma executives view partnerships as business-critical, around half report failure rates exceeding 60%. Baringa is on a mission to help life sciences organisations get partnering right.

From scaling up advanced therapy manufacturing to harnessing the power of digital and automation, Ed Samuel, the new COO of the CGT Catapult, discusses how collaboration and innovation will shape the next phase of the UK’s cell and gene therapy ecosystem.

Last week, the Teesside business community and local guests came together at Wilton Centre, near Redcar, to commemorate the 50th anniversary of the iconic research space, a renowned landmark in Europe’s R&D landscape.

NRG announced the expansion of its team with the addition of three senior appointments in newly created roles: Sarah Almond as VP of Translational Biology; David Brocklebank as Director of Clinical Operations; and Kathryn Oliver as Director of Project Management.

Coulter Partners completed a search assignment for Tristel plc (AIM: TSTL) and is pleased to announce the placement of Anna Wasyl as Chief Financial Officer.

Dr Graham Spittle CBE has been appointed as the new Chair of Trustees at the Rosalind Franklin Institute from November 2025.

​​​​​​​Following a landmark TechBio Week, we reflect with some insights from our flagship conference on the transformative potential for growth of technological advances in the sector.

Coulter Partners successfully completed a search assignment Proveca and is pleased to announce the placement of Gregory Reinaud as Chief Operating Officer (COO).

A new science specialist sixth form is set to open next year, based at Sandwich Science and Innovation Campus, Discovery Park. The new sixth form is named Carbon 6 Academy of Science, ideal for ambitious students aged 16-18 with a passion for science and maths.

Caroline founded Amici in 2005, building a company that scientists trust to power intelligent LabOps, the discipline behind efficient, compliant, and cost-effective labs. Today, Amici partners with biotech's and major pharma companies across the UK, Europe, and the US.

Precision BioSearch is delighted to have supported Maxion Therapeutics, a pioneering biotechnology company developing antibody-based drugs for ion channel and GPCR-driven diseases, with the appointment of Joel Edwards as Chief Business Officer.

MDC will accelerate innovative life science business growth through upskilling and capability development

Every two years, Cytiva surveys 1250 biopharma executives across 22 countries and asks them to rate, on a scale of 0 to 10, the biopharma ecosystem across six pillars: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, government policy and regulation.

Michelle Jones appointed as President and Gianni Chessari appointed as CSO.

Executive with broad and deep experience across energy and healthcare sectors joins the life sciences leader to drive growth in resins, filtration, and cell culture media business.

Chemify scales up operations at Glasgow’s newest purpose-built life science facility Health Innovation Hub. Chemify joins the Digital Health Validation Lab (DHVL) who will all be welcomed as the first tenants of HiH when it opens this year.

Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, today announces the appointment of Dr. Katie Chapman as Chief Scientific Officer (CSO).